Psychiatry Archives -

Sosei Heptares has taken another of its partnered G protein-coupled receptor (GPCR) programmes into mid-stage clinical trials, earning

Sosei Heptares banks $30m milestone in Neurocrine Bio alliance

https://pharmaphorum.com/news/sosei-heptares-banks-30m-milestone-in-neurocrine-bio-alliance/

News/ News/ R&D

VistaGen’s horizons may shrink after clinical trial setback

Phil Taylor central nervous system, Psychiatry, social anxiety disorder, VistaGen Therapeutics 0 Comment

Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed

VistaGen’s horizons may shrink after clinical trial setback

https://pharmaphorum.com/news/vistagens-horizons-may-shrink-after-clinical-trial-setback/

News/ News/ R&D

AbbVie adds to Vraylar data as FDA considers depression use

Phil Taylor AbbVie, depression, Psychiatry, Vraylar 0 Comment

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression,

AbbVie adds to Vraylar data as FDA considers depression use

https://pharmaphorum.com/news/abbvie-adds-to-vraylar-data-as-fda-considers-depression-use/

Market Access/ News/ News

Teva’s long-acting schizophrenia drug rejected by FDA

Phil Taylor MedinCell, Psychiatry, regulatory, schizophrenia, Teva 0 Comment

Teva’s long haul to a turnaround of its business has been dealt a blow by the FDA, which

Teva’s long-acting schizophrenia drug rejected by FDA

https://pharmaphorum.com/news/tevas-long-acting-schizophrenia-drug-rejected-by-fda/

Market Access/ News/ News

BioXcel gets first approval for agitation drug Igalmi

Phil Taylor agitation, BioXcel, bipolar disorder, Igalmi, Psychiatry, regulatory approval, schizophrenia 0 Comment

BioXcel Therapeutics has claimed its first product approval, getting a green light from the FDA for Igalmi as

BioXcel gets first approval for agitation drug Igalmi

https://pharmaphorum.com/news/bioxcel-gets-first-approval-for-agitation-drug-igalmi/

Market Access/ News/ News

AbbVie files Vraylar as add-on therapy for depression in US

Phil Taylor AbbVie, depression, Psychiatry, regulatory, Vraylar 0 Comment

AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include

AbbVie files Vraylar as add-on therapy for depression in US

https://pharmaphorum.com/news/abbvie-files-vraylar-as-add-on-therapy-for-depression-in-us/

News/ News/ R&D

Sage, Biogen’s zuranolone looks approvable, but will it sell?

Phil Taylor Biogen, depression, Psychiatry, Sage Therapeutics, zuranolone 0 Comment

Last year, the first phase 3 trial of Sage Therapeutics and Biogen’s antidepressant hopeful zuranolone hit its efficacy

Sage, Biogen’s zuranolone looks approvable, but will it sell?

https://pharmaphorum.com/news/sage-biogens-zuranolone-looks-approvable-but-will-it-sell/

News/ News/ R&D

Compass points to positive psilocybin trial, but shares fall

Phil Taylor Compass Pathways, depression, psychedelics, Psychiatry 0 Comment

Compass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was

Compass points to positive psilocybin trial, but shares fall

https://pharmaphorum.com/news/compass-points-to-positive-psilocybin-trial-but-shares-fall/

Market Access/ News/ News

Biogen, Sage prep 2022 filing for depression drug zuranolone

Phil Taylor Biogen, depression, fda, Psychiatry, Sage Therapeutics, zuranolone 0 Comment

The renaissance of Biogen and Sage Therapeutics antidepressant zuranolone continues, with the companies indicating they now plan to

Biogen, Sage prep 2022 filing for depression drug zuranolone

https://pharmaphorum.com/news/biogen-sage-prep-2022-filing-for-depression-drug-zuranolone/

Trending

Psychiatry

Login